Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-driven nivolumab + ipilimumab or VEGFR TKI in treatment-naïve metastatic kidney cancer
2024-520045-23-00Phase 2Authorised
- Sponsor
- Al Rayyan Tourism Investment Company
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab and ipilimumab in renal cell carcinoma (RCC) (2 arms), sponsored by Al Rayyan Tourism Investment Company. Planned start Jan 2025; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-520045-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520045-23-00.